Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Healer: KN026 + HB1801 in Neoadjuvant HER2+ Breast Cancer
NCT06747338Phase 3Active, not recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Nanoparticles, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab, albumin-bound docetaxel in breast cancer, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Dec 2024; status: active, not recruiting.
02
Drugs
anbenitamabalbumin-bound docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06747338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747338.